Screening of genetic alterations related to non-syndromic hearing loss using MassARRAY iPLEX (R) technology

Author(s)

Costa Melo Svidnicki, Maria Carolina ^[1] ; Silva-Costa, Sueli Matilde ^[1] ; Ramos, Priscila Zonzini ^[1] ; Pereira dos Santos, Nathalia Zocal ^[1] ; Arrojo Martins, Fabio Tadeu ^[1] ; Castilho, Arthur Menino ^[2] ; Sartorato, Edi Lucia ^[1]

Affiliation

^[1] Univ Campinas Unicamp, Mol Biol & Genet Engn Ctr CBMEG, Human Mol Genet Lab, Sao Paulo - Brazil

^[2] Univ Campinas Unicamp, Fac Med Sci, ENT Dept, Sao Paulo - Brazil

• Document type: Journal article
• Source: BMC MEDICAL GENETICS; v. 16, SEP 23 2015.
• Web of Science Citations: 11

Abstract

Background: Recent advances in molecular genetics have enabled to determine the genetic causes of non-syndromic hearing loss, and more than 100 genes have been related to the phenotype. Due to this extraordinary genetic heterogeneity, a large percentage of patients remain without any molecular diagnosis. This condition imply the need for new methodological strategies in order to detect a greater number of mutations in multiple genes. In this work, we optimized and tested a panel of 86 mutations in 17 different genes screened using a high-throughput genotyping technology to determine the molecular etiology of hearing loss. Methods: The technology used in this work was the MassARRAY iPLEX (R) platform. This technology uses silicon chips and DNA amplification products for accurate genotyping by mass spectrometry of previous reported mutations. The generated results were validated using conventional techniques, as direct sequencing, multiplex PCR and RFLP-PCR. Results: An initial genotyping of control subjects, showed failures in 20 % of the selected alterations. To optimize these results, the failed tests were re-designed and new primers were synthesized. Then, the specificity and sensitivity of the panel demonstrated values above 97 %. Additionally, a group of 180 individuals with NSHL without a molecular diagnosis was screened to test the diagnostic value of our panel, and mutations were identified in 30 % of the cases. In 20 % of the individuals, it was possible to explain the etiology of the HL. Mutations in GJB2 gene were the most prevalent, followed by other mutations in in SLC26A4, CDH23, MT-RNR1, MYO15A, and OTOF genes. Conclusions: The MassARRAY technology has the potential for high-throughput identification of genetic variations. However, we demonstrated that optimization is required to increase the genotyping success and accuracy. The developed panel proved to be efficient and cost-effective, being suitable for applications involving the molecular diagnosis of hearing loss. (AU)